Evogene (EVGN) Net Equity Issued and Repurchased (2020 - 2024)
Evogene (EVGN) posted Net Equity Issued and Repurchased of $5.4 million for Q4 2024, up 14432.43% sequentially from $37000.0 in Q3 2024, and up 11848.89% YoY from N/an in Q1 2024.
Evogene (EVGN) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends
Evogene has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $5.4 million in Q4 2024.
- Quarterly Net Equity Issued and Repurchased rose 11848.89% year-over-year to $5.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $5.4 million (down 1.56% YoY) and the FY2025 annual result came in at $4.3 million, down 22.13% from the prior year.
- Net Equity Issued and Repurchased improved to $5.4 million in Q4 2024 per EVGN's latest filing, from $37000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $27.1 million in Q1 2021 and troughed at $3000.0 in Q1 2024.
- A 4-year average of $4.8 million and a median of $814000.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 11848.89% in 2024, down 99.54% in 2024.
- Over 4 years, Net Equity Issued and Repurchased stood at $8.9 million in 2020, then tumbled by 81.26% to $1.7 million in 2021, then plunged by 97.29% to $45000.0 in 2023, then surged by 11848.89% to $5.4 million in 2024.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $5.4 million, $37000.0, and $83000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.38 Mn |
| Dec 31, 2024 | 5.38 Mn |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Sep 30, 2023 | 8.07 Mn |
| Sep 30, 2023 | 8.07 Mn |
| Jun 30, 2023 | 68,000.00 |
| Jun 30, 2023 | 68,000.00 |
| Mar 31, 2023 | 268,000.00 |
| Mar 31, 2023 | 268,000.00 |
| Sep 30, 2021 | 1.66 Mn |
| Sep 30, 2021 | 1.66 Mn |
| Jun 30, 2021 | 814,000.00 |
| Jun 30, 2021 | 814,000.00 |